The "Malaysia National Action Plan for Cervical Cancer Elimination (2021-2030)" released by the Ministry of Health Malaysia is the country's core initiative in response to the World Health Organization's call to "eliminate cervical cancer within this century." This plan not only sets clear elimination goals but also establishes three core systems: "expanding HPV vaccination, strengthening cervical cancer screening, and improving the treatment of precancerous lesions and cancer." The plan aims to fully achieve the 90-70-90 targets by 2030 (i.e., 90% HPV vaccination coverage, 70% screening coverage, and 90% treatment rate for precancerous lesions).

The National Strategic Plan for Ending AIDS 2016-2030 (NSPEA) in Malaysia, led by the HIV/STI Section of the Ministry of Health Malaysia, envisions achieving 'zero new infections, zero discrimination, and zero AIDS-related deaths,' with the goal of ending the AIDS epidemic by 2030.

In July 2024, the Malaysian Ministry of Health released a news statement regarding the "Summary Report of the Malaysian National Cancer Registry 2017-2021". This report, compiled by the National Cancer Registry of the National Cancer Institute of Malaysia, is the third five-year authoritative report following the "Summary Report of the Malaysian National Cancer Registry 2012-2016" published in 2019. It comprehensively reviews Malaysia's cancer disease burden and deeply analyzes the trends in cancer incidence. It is also the latest and most comprehensive core data on cancer publicly available on the official website of the National Cancer Institute of Malaysia.

As an outstanding partner in the field of medical health compliance, Shinying (Shanghai) Medical Technology Co., Ltd. (Shinying Med) has officially signed an exclusive strategic cooperation agreement for medical products in Southeast Asia and the Middle East with Epower Consulting, a top consulting firm deeply engaged in these markets, in Shanghai.

With dual support from policy dividends and market potential, Malaysia is becoming a stronghold for Chinese pharmaceutical and medical device companies expanding into ASEAN. As competition in the domestic medical market intensifies, going abroad has become an essential path for Chinese companies to achieve strategic development.

On September 24, 2021, the National Medical Products Administration of China officially launched the application process for the Pharmaceutical Inspection Cooperation Scheme (PIC/S) pre-joining program. This move will not only accelerate the internationalization of China's drug regulatory system, effectively ensuring public medication safety and health rights, but will also comprehensively enhance the quality management efficiency in the domestic pharmaceutical production sector, aiding the pharmaceutical industry in deeply integrating into the global market.

The "Malaysia National Action Plan for Cervical Cancer Elimination (2021-2030)" released by the Ministry of Health Malaysia is the country's core initiative in response to the World Health Organization's call to "eliminate cervical cancer within this century." This plan not only sets clear elimination goals but also establishes three core systems: "expanding HPV vaccination, strengthening cervical cancer screening, and improving the treatment of precancerous lesions and cancer." The plan aims to fully achieve the 90-70-90 targets by 2030 (i.e., 90% HPV vaccination coverage, 70% screening coverage, and 90% treatment rate for precancerous lesions).

The National Strategic Plan for Ending AIDS 2016-2030 (NSPEA) in Malaysia, led by the HIV/STI Section of the Ministry of Health Malaysia, envisions achieving 'zero new infections, zero discrimination, and zero AIDS-related deaths,' with the goal of ending the AIDS epidemic by 2030.

In July 2024, the Malaysian Ministry of Health released a news statement regarding the "Summary Report of the Malaysian National Cancer Registry 2017-2021". This report, compiled by the National Cancer Registry of the National Cancer Institute of Malaysia, is the third five-year authoritative report following the "Summary Report of the Malaysian National Cancer Registry 2012-2016" published in 2019. It comprehensively reviews Malaysia's cancer disease burden and deeply analyzes the trends in cancer incidence. It is also the latest and most comprehensive core data on cancer publicly available on the official website of the National Cancer Institute of Malaysia.